Form 4/A for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-09-05 00:00:00 ET · period of report 2023-08-23 · accession 0000950170-24-104191 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2024-09-05 | 2023-08-23 | AMLX | FRATES JAMES M | CFO | M - OptEx | $6.88 | +18.2K | 73.8K | +33% | +$125.0K |
| DA | 2024-09-05 | 2023-08-23 | AMLX | FRATES JAMES M | CFO | M - OptEx | $0.00 | -18.2K | 363.8K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-23 | M | A | 18,165 | $6.88 | 73,841 | D | — | — | (F1) On August 24, 2023, a Form 4 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 5 of Table I by 32,500 shares due to an administrative error. This Form 4 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date, as well as the corresponding amounts that were carried forward on Form 4 reports subsequently filed on behalf of the Reporting Person. |
| 2 | Derivative | Stock Option (right to buy) | 2023-08-23 | M | D | 18,165 | $0.00 | 363,835 | D | $6.88 · — to 2031-01-25 | 18,165 Common Stock | (F3) 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter. |